In vitro assays have shown that recombinant KLK6 proteins are capable of extracellular matrix (ECM) protein digestion and neutralising KLK6 antibodies can decrease the rate of migration of ovarian cancer cell lines, further supporting this hypothesis (Ghosh et al, 2004). This evidence concerns the gene KLK6 and ovarian carcinoma.